One-Year Health Care Utilization and Recurrence After Incisional Hernia Repair in the United States: A Population-Based Study Using the Nationwide Readmission Database.

BACKGROUND: Most data on health care utilization after incisional hernia (IH) repair are limited to 30-days and are not nationally representative. We sought to describe nationwide 1-year readmission burden after IH repair (IHR). METHODS: Patients undergoing elective IHR discharged alive were identified using the 2010-2014 Nationwide Readmission Database. Transfers and incomplete follow-up were excluded. Descriptive statistics were used to describe rates of 1-year readmission, IH recurrence, and bowel obstruction. Cox regression allowed identification of factors associated with 1-year readmissions. Generalized linear models were used to estimate predicted mean difference in cumulative costs/year, which allowed estimation of IHR readmission costs/year nationwide. RESULTS: Of 15,935 identified patients, 19.35% were readmitted within 1 y. Patients who were readmitted differed by insurance, Charlson index, illness severity, smoking status, disposition, and surgical approach compared with those who were not (P < 0.05). Of readmitted patients, 39.3% returned within 30 d; 50.9% and 25.6% were due to any and infectious complications, respectively; 25.6% presented to a different hospital; 35.4% required reoperation; 5.4% experienced bowel obstruction; and 5% had IHR revision. Factors associated with readmissions included Medicare (hazard ratio [HR] 1.46 [95% confidence interval 1.19-1.8]; P < 0.01) or Medicaid (HR 1.42 [1.12-1.8], P < 0.01); chronic pulmonary disease (1.38 [1.17-1.64], P < 0.01), and anemia (1.36, [1.05-1.75], P = 0.02). Readmitted patients had higher 1-year cumulative costs (predicted mean difference $12,190 [95% CI: 10,941-13,438]; P < 0.01). Nationwide cost related to readmissions totaled $90,196,248/y. CONCLUSIONS: One-year readmissions after IHR are prevalent and most commonly due to postoperative complications, especially infections. One-third of readmitted patients require a subsequent operation, and 5% experience IH recurrence, intensifying the burden to patients and on the health care system.

Is It Safe to Manage Acute Cholecystitis Nonoperatively During Pregnancy?: A Nationwide Analysis of Morbidity According to Management Strategy.

OBJECTIVES: To compare cholecystectomy (CCY) and nonoperative treatment (no-CCY) for acute cholecystitis in pregnancy. SUMMARY OF BACKGROUND DATA: Current Society of Gastrointestinal and Endoscopic Surgery guidelines recommend CCY over nonoperative management of acute cholecystitis during pregnancy, and the American College of Obstetricians and Gynecologists recommend medically necessary surgery regardless of trimester. This approach has been recently questioned. METHODS: Pregnant women admitted with acute cholecystitis were identified using the Nationwide Readmission Database 2010-2015. Propensity-score adjusted logistic regression models were used to compare CCY and no-CCY. The primary outcome was a composite measure of adverse maternal-fetal outcomes (intrauterine death/stillbirth, poor fetal growth, abortion, preterm delivery, C-section, obstetric bleeding, infection of the amniotic fluid, venous thromboembolism). RESULTS: There were 6390 pregnant women with acute cholecystitis: 38.2% underwent CCY, of which 5.1% were open. Patients were more likely to be managed operatively in their second trimester (First 43.9%, Second 59.1%, Third 34.2%; P < 0.01). Patients managed with CCY did not differ in age, insurance, income, Charlson Comorbidity Index, diabetes or obesity when compared to no-CCY (all P > 0.05), but were less likely to have a previous C-section, gestational diabetes, preeclampsia/eclampsia or be in the third trimester (P ≤ 0.01). Risk-adjusted analyses showed that no-CCY was associated with significantly increased maternal-fetal complications during the index admission [odds ratio 3.0 (95% confidence interval 2.08-4.34), P < 0.01] and 30-day readmissions [odds ratio 1.61 (confidence interval % CI 1.12-2.32), P < 0.01]. CONCLUSIONS: Contrary to current guidelines, most pregnant women admitted in the US with acute cholecystitis are managed nonoperatively. This is associated with over twice the odds of maternal-fetal complications in addition to increased readmissions.

Six-month readmissions after bariatric surgery: Results of a nationwide analysis.

BACKGROUND: Morbidity and mortality after laparoscopic bariatric surgery have decreased steadily during the past 2 decades. National data on the rates at which these patients may require return to the hospital beyond 30 days are lacking. We aimed to determine the national burden and causes of readmission after the 3 most common bariatric procedures in the United States. METHODS: All adult patients with morbid obesity (>18 years old) who underwent a laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, or laparoscopic gastric bypass between 2010 and 2015 were identified using International Classification of Diseases, Ninth Revision codes from the Nationwide Readmission Database. The Nationwide Readmission Database permits longitudinal tracking of patients between hospital admissions and allows for nationally weighted estimates. The primary outcome was 180-day readmission; secondary outcomes included causes, mortality, time to readmission, costs, and procedures during readmission. Multivariate logistic regression models were used to determine factors associated with increased 180-day readmission after adjusting for differences in patient and hospital characteristics. RESULTS: Records from 228,043 patients were identified, of whom 10.1%, 36.1%, and 53.9% underwent laparoscopic adjustable gastric banding, laparoscopic sleeve gastrectomy, and laparoscopic gastric bypass, respectively. The overall 180-day readmission rate was 10.8% (laparoscopic adjustable gastric banding 8.3%, LGS 7.8% and laparoscopic gastric bypass 13.2%). Readmission analysis showed that 64.5% were directly relates directly to the index procedure, 31.2% were readmitted to a different hospital, the median time to readmission was 28 days (interquartile ratio 9-77), 23.9% had a gastrointestinal procedure, and 0.48% died within the 180-day readmissions. Factors independently associated with increased readmission were the following: greater preoperative comorbidities (Charlson Comorbidity Index ≥2, odds ratio 1.32; 95% confidence interval, 1.22-1.44); either Medicare status (1.84 [1.72-1.97]) or Medicaid status (1.60 [1.48-1.73]) relative to private insurance; moderate (1.09 [1.03-1.15]) or major (1.33 [1.13-1.56]) severity of illness relative to minor Nationwide Readmission Database-provided severity of illness; nonresident of state where they were admitted initially (1.49 [1.31-1.69]); discharge to a health care system other than home (1.70 [1.46-1.97]); short-term hospital 1.70 [1.46-1.97]); admission to private hospital (1.11 [1.01-1.22]) relative to nonprofit hospital; prolonged duration of initial hospital stay (1.81 [1.70-1.92]); and a serious adverse event occurring during the index admission (1.20 [1.02-1.42]). Patients who were readmitted had an incremental mean difference of $15,781 (95% confidence interval, $15,168-$16,394.4; P < .001) in total costs. CONCLUSION: Readmissions after bariatric surgery continue to occur even 6 months after discharge. Most of these readmissions were related directly to the index procedure. Almost a fourth of those patients who were readmitted d required a procedure and almost a third presented to a different hospital than the hiatal of their initial operation. These readmissions carry a substantial burden for the health care system and may impair quality of life for patients. Strategies targeted to prevent readmissions beyond the traditional 30-day benchmark are warranted in this population.

Comparative Quantitative Lymph Node Assessment in Localized Esophageal Cancer Patients After R0 Resection With and Without Neoadjuvant Chemoradiation Therapy.

INTRODUCTION: The effects of neoadjuvant chemoradiation therapy on lymph node retrieval during esophagectomy for patients with esophageal cancer are unclear. The aim of this study was to quantify lymph node retrieval after R0 esophagectomy and to assess its impact on overall survival in induction therapy patients. METHODS: One hundred seventy-four consecutive patients underwent esophagectomy with or without induction therapy from 2008 to 2015 for esophageal cancer. Total lymph nodes, positive lymph nodes, and lymph node ratios were compared between two groups of patients: those treated with either upfront surgery or those treated with neoadjuvant chemoradiation therapy followed by surgery. Comparisons were made using Student's t test. Overall survival was obtained and compared using Kaplan Meier survival curves. RESULTS: Total lymph node counts were less in the induction therapy group (p = 0.027), while positive lymph node counts and lymph node ratios did not differ between groups (p = 0.262 and p = 0.310, respectively). In the neoadjuvant chemoradiation followed by surgery group, overall survival was significantly shorter for patients who had any positive lymph nodes in the pathologic specimen (p = 0.0065). CONCLUSIONS: Total lymph node counts were significantly lower in the induction therapy group, while positive lymph node counts and lymph node ratios did not differ from the upfront surgery group. Although overall survival was not different between groups, it was decreased within the induction therapy cohort among those who had any positive lymph nodes retrieved at surgery. This study confirms that unstratified gross lymph node counts do not substantially relate to prognosis in the heterogeneous population of locally advanced esophageal cancer patients who may or may not have had neoadjuvant chemoradiation.

Surgical Apgar score (SAS) predicts perioperative morbidity, mortality, and length of stay in patients undergoing esophagectomy at a high-volume center.

BACKGROUND: Esophagectomy carries considerable morbidity. Many studies have evaluated factors to predict patients at risk. This study aimed to determine whether the surgical Apgar score (SAS) predicts complications and length of stay (LOS) for patients undergoing esophagectomy. STUDY DESIGN: We evaluated 212 patients undergoing esophagectomy. Postoperative complications were graded using the Clavien-Dindo scale and the SAS was determined. Association of SAS with incidence of complications was evaluated using the Cochran-Armitage trend test between grouped SAS scores (0-2, 3-4, 5-6, 7-8, 9-10) and each of the outcomes. Correlation of SAS with LOS was evaluated using competing risks proportional hazards regression. RESULTS: The average patient age was 63.5 years (range 31-86), and the average blood loss was 284 mL (range 50-4000). The median LOS was 10 days. There was a significant association between SAS and grade 2 or higher (P = 0.0002) and grade 3 or higher (P < 0.0001) complications. The perioperative mortality rate was 5.2% (n = 11) with lower SAS being associated with greater mortality. LOS was also associated with SAS (P < 0.0001). CONCLUSIONS: We demonstrate that SAS is a significant predictor of complications and LOS for patients undergoing esophagectomy. SAS should be used to identify lower risk patients to prioritize use of critical care beds and hospital resources.